Tau Antibodies Block Aggregation Propagation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and other neurodegenerative disorders associated with tau aggregation are inadequate, as they fail to effectively prevent the spread of tau pathology within the brain, which progresses through existing neural networks, leading to significant cognitive decline and loss of independence.
Innovation Solution
Development of specific antibodies that bind to tau, such as HJ8 and HJ9 series, which can slow and reduce the propagation of tau aggregation by blocking the conversion of monomeric tau into aggregated forms, preventing entry of tau aggregates into neighboring cells, and decreasing tau seeding activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease are used, then patient care is provided, but they fail to effectively prevent the spread of tau pathology within the brain
Solution Approach 1:
The patent introduces antibodies as intermediary molecules that bind to tau aggregates and block their propagation. These antibodies act as mediators between the immune system and tau pathology, preventing the transfer of aggregated tau between neurons while maintaining normal neural function and communication.
Solution Approach 2:
The patent applies preliminary anti-action by administering antibodies that preemptively block tau aggregate propagation before significant neurodegeneration occurs. The antibodies are designed to intercept and neutralize tau seeds early in their propagation pathway, preventing the conversion of monomeric tau into aggregated forms before they can spread extensively throughout the brain.
2Stability of the object's composition
If tau aggregation is allowed to progress, then natural disease course occurs, but cognitive function and independence are lost
Solution Approach 1:
The patent converts the harmful effect of tau aggregation into a beneficial diagnostic and therapeutic opportunity. By targeting the aggregation process itself with antibodies, the patent transforms the pathological mechanism into a treatable target, where the same aggregation-prone tau that causes disease can be intercepted and neutralized by antibody binding, preventing further harm while maintaining cognitive function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies effectively inhibit the spread of tau aggregates, reducing intracellular aggregation and tau seeding activity, potentially slowing the progression of neurodegenerative diseases by targeting tau pathology directly.
Implementation Method 1
specific antibodies that bind to tau, such as HJ8 and HJ9 series, which can slow and reduce the propagation of tau aggregation
Data Source
AI summary
This invention relates to antibodies to tau and methods of use thereof.